Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleftherios Mylonakis

Showing results (21-30 of 451) with videos related to

Pageof 46
Sort By:
Virulence|December 17, 2014
Effector triggered manipulation of host immune response elicited by different pathotypes of Escherichia coliElamparithi Jayamani, Eleftherios Mylonakis
Annals of Internal Medicine|January 3, 2022
80% of patients with COVID-19 have ≥1 long-term effect at 14 to 110 d after initial symptomsMatthew Kaczynski, Eleftherios Mylonakis
European Journal of Clinical Investigation|April 9, 2015
Diagnosis of invasive aspergillosis: recent developments and ongoing challengesMarios Arvanitis, Eleftherios Mylonakis
Expert Opinion on Investigational Drugs|May 31, 2006
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitationsGeorge Aperis, Eleftherios Mylonakis
Annals of Internal Medicine|June 17, 2020
In MRSA bacteremia, adding a β-lactam to usual care did not improve a composite outcome at 90 daysEleftheria Atalla, Eleftherios Mylonakis
Expert Review of Anti-Infective Therapy|June 30, 2017
Colonization and infection with extended-spectrum beta-lactamase producing Enterobacteriaceae in patients with malignancyMichail Alevizakos, Eleftherios Mylonakis
Eukaryotic Cell|April 19, 2011
Killing of Candida albicans filaments by Salmonella enterica serovar Typhimurium is mediated by sopB effectors, parts of a type III secretion systemYounghoon Kim, Eleftherios Mylonakis
Annals of Internal Medicine|October 20, 2017
Triple therapy reduced mortality more than oseltamivir alone in patients admitted for severe influenza infectionNikolaos Andreatos, Eleftherios Mylonakis
Annals of Internal Medicine|December 2, 2024
After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 yStephanos Vassilopoulos, Eleftherios Mylonakis
Annals of Internal Medicine|April 1, 2024
In adults with post-COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 moDeepa Gotur, Eleftherios Mylonakis
Pageof 46

Showing results (21-30 of 451) with videos related to

Sort By:
Pageof 46
Virulence|December 17, 2014
Effector triggered manipulation of host immune response elicited by different pathotypes of Escherichia coliElamparithi Jayamani, Eleftherios Mylonakis
Annals of Internal Medicine|January 3, 2022
80% of patients with COVID-19 have ≥1 long-term effect at 14 to 110 d after initial symptomsMatthew Kaczynski, Eleftherios Mylonakis
European Journal of Clinical Investigation|April 9, 2015
Diagnosis of invasive aspergillosis: recent developments and ongoing challengesMarios Arvanitis, Eleftherios Mylonakis
Expert Opinion on Investigational Drugs|May 31, 2006
Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitationsGeorge Aperis, Eleftherios Mylonakis
Annals of Internal Medicine|June 17, 2020
In MRSA bacteremia, adding a β-lactam to usual care did not improve a composite outcome at 90 daysEleftheria Atalla, Eleftherios Mylonakis
Expert Review of Anti-Infective Therapy|June 30, 2017
Colonization and infection with extended-spectrum beta-lactamase producing Enterobacteriaceae in patients with malignancyMichail Alevizakos, Eleftherios Mylonakis
Eukaryotic Cell|April 19, 2011
Killing of Candida albicans filaments by Salmonella enterica serovar Typhimurium is mediated by sopB effectors, parts of a type III secretion systemYounghoon Kim, Eleftherios Mylonakis
Annals of Internal Medicine|October 20, 2017
Triple therapy reduced mortality more than oseltamivir alone in patients admitted for severe influenza infectionNikolaos Andreatos, Eleftherios Mylonakis
Annals of Internal Medicine|December 2, 2024
After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 yStephanos Vassilopoulos, Eleftherios Mylonakis
Annals of Internal Medicine|April 1, 2024
In adults with post-COVID-19 conditions, a synbiotic preparation, SIM01, alleviated some symptoms at 6 moDeepa Gotur, Eleftherios Mylonakis
Pageof 46